Description: PILA PHARMA AB (publ) operates as a clinical stage pharmaceutical company in Sweden. It is developing XEN-D0501, a TRPV1 antagonist that has completed two phase 2b clinical trials for type 2 diabetes. The company was incorporated in 2014 and is based in Malmö, Sweden.
Home Page: pilapharma.com
Norra Vallgatan 72
Malmö,
211 22
Sweden
Phone:
46 7 39 03 69 69
Officers
| Name | Title |
|---|---|
| Ms. Dorte Xenia Gram | Founder, Chairman & Chief Scientific Officer |
| Ms. Elna Lembrer Astrom | Chief Financial Officer |
| Mr. Gustav Hanghoj Gram | Chief Executive Officer |
| Mr. Miguel Lecumberri | Head of Compliance & Legal Affairs |
| Mr. Masoud Alavi | Head of Corporate Visual Communication |
| Mr. Andy Makin | Head of Toxicology |
| Ms. Maura McArdle | Head of BD & Quay Pharma |
| Mr. Mike Frodsham | CTO of Quay Pharma |
| Ms. Alison Foster | Head of Pre-Clinical - Quay Pharma |
| Mr. Simon Hamilton | Head of Global Business Development - Almac |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 39.9527 |
| Price-to-Sales TTM: | 9.1129 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 1 |